Exact Sciences (company)

Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer.

This article is about an American bioscience company. For the branch of sciences, see Exact sciences.
Exact Sciences Corporation
Company typePublic
Traded as
  • Nasdaq: EXAS
  • Russell 1000 component
IndustryMolecular diagnostics
Founded1995 (1995) in Marlborough, Massachusetts
Founders
  • Stanley Lapidus
  • Anthony P. Shuber
HeadquartersMadison, Wisconsin, U.S.
Key people
  • Kevin Conroy
  • (Chairman, President & CEO)
  • Jorge Garces
  • (Chief Science Officer)
ProductsCologuard, Oncotype DX, Oncotype MAP
Revenue US$2.08 billion (2022)
US$−594 million (2022)
Net income
 US$−624 million (2022)
Total assets US$6.23 billion (2022)
Total equity US$3.04 billion (2022)
Number of employees
6,400 (Dec 2022)
Subsidiaries
Subsidiary List
  • Biomatrica
  • Exact Sciences Development
  • Exact Sciences Innovation
  • Exact Sciences International
  • Exact Sciences Laboratories
  • Exact Sciences Thrive
  • Genomic Health
  • Paradigm Diagnostics
  • Prevention Genetics
Websiteexactsciences.com
Footnotes / references
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.